The Wolverine peptide stack combines BPC-157 (250-500 mcg daily) and TB-500 (2-5 mg twice weekly) for injury recovery. BPC-157 builds new blood vessels at the injury site through VEGF upregulation. TB-500 mobilizes repair cells systemically through actin regulation. The name comes from the X-Men character's regenerative healing. Neither peptide is FDA-approved. No study has tested the combination.
| Feature | BPC-157 | TB-500 | Combined Stack |
|---|---|---|---|
| Mechanism | Angiogenesis, NO system | Actin regulation, cell migration | Complementary pathways |
| Best for | Localized injury (one site) | Systemic repair (multiple sites) | Full-spectrum healing |
| Standard dose | 250-500 mcg/day | 2-5 mg 2x/week | Both at standard doses |
| Half-life | ~4 hours | ~2-7 days | N/A |
| Route | Subcutaneous (near injury) | Subcutaneous (any site) | Both subcutaneous |
| Monthly cost | $40-80 | $60-120 | $100-200 |
| Human trials | 3 pilot studies | Phase 2 (dry eye, wounds) | Zero combination studies |
The Wolverine stack is the most popular peptide pairing in the recovery community. The complementary mechanism theory is plausible. The evidence gap is real. This guide covers dosing protocols, the science behind each peptide, blend vs. separate purchasing, and an honest assessment of what the evidence supports.
For individual peptide details, see our BPC-157 benefits guide and what TB-500 does. This is educational content about research compounds.
Get your custom peptide protocol:
- Tailored to your body and goals
- Precise dosing and cycle length
- Safe stacking combinations
- Backed by peer-reviewed studies
- Ready in under 2 minutes
Why These Two Peptides Together
BPC-157 and TB-500 target different phases of tissue repair through different biological pathways. This is why the community pairs them rather than doubling down on one.
BPC-157 builds the infrastructure. It upregulates VEGF (vascular endothelial growth factor), creating new blood vessels at the injury site. More blood supply means more oxygen, nutrients, and immune cells reaching damaged tissue. BPC-157 also modulates nitric oxide signaling and stimulates fibroblast proliferation for collagen production. It works best when injected near the injury site because its 4-hour half-life limits systemic distribution.
TB-500 sends the repair cells. It regulates actin polymerization, which controls how cells move and restructure. TB-500 promotes endothelial cell migration, reduces NF-kB-driven inflammation, and supports stem cell mobilization. Its 2-7 day half-life means it distributes systemically, reaching multiple injury sites regardless of injection location.
The complementary theory: BPC-157 builds the roads (blood vessels). TB-500 sends the repair trucks (migrating cells). One handles local infrastructure. The other handles systemic logistics. The pathways do not overlap, which is why researchers hypothesize synergy rather than redundancy.
This synergy has never been tested in a controlled study. Every claim about the combination is extrapolated from individual compound research. For a direct comparison, see our BPC-157 vs TB-500 guide.
Dosing Protocols
Three protocol tiers based on experience level and injury severity.
Beginner Protocol (4-6 weeks)
| Peptide | Dose | Frequency | Injection Site |
|---|---|---|---|
| BPC-157 | 250 mcg | Once daily | Subcutaneous, near injury |
| TB-500 | 2 mg | Twice per week | Subcutaneous, abdomen |
Standard Protocol (6-8 weeks)
| Peptide | Dose | Frequency | Injection Site |
|---|---|---|---|
| BPC-157 | 500 mcg | Once daily | Near injury, rotate sides |
| TB-500 | 2.5 mg | 2x/week (loading 4 wks), then 1x/week | Abdomen |
Advanced Protocol (8-12 weeks)
| Peptide | Dose | Frequency | Injection Site |
|---|---|---|---|
| BPC-157 | 500 mcg | Twice daily (AM near injury, PM abdomen) | Split sites |
| TB-500 | 5 mg | 2x/week (loading 6 wks), then 2.5 mg 1x/week | Abdomen |
TB-500 protocols typically include a loading phase (higher frequency for 4-6 weeks) followed by a maintenance phase (reduced frequency). BPC-157 does not require loading because of its shorter half-life.
Both peptides are reconstituted from lyophilized powder with bacteriostatic water. Use our reconstitution calculator for exact measurements. For injection technique, see our how to inject peptides guide.
Blend Products vs. Separate Vials
You can purchase BPC-157 and TB-500 as a pre-mixed blend or as separate vials. Each approach has trade-offs.
| Factor | Blend (Pre-Mixed) | Separate Vials |
|---|---|---|
| Convenience | High (one vial, one injection) | Lower (two reconstitutions, two injections) |
| Dose flexibility | Low (fixed ratio) | High (adjust each independently) |
| Local injection | Cannot split (both go to same site) | BPC near injury + TB-500 abdomen |
| Cost per week | $35-50/week | $25-40/week |
| Available formats | 10 mg (5+5), 20 mg (10+10) | Any size |
When to choose separate vials: If you have a specific injury and want BPC-157 injected near the site for maximum local effect. If you want to adjust doses independently based on response.
When to choose a blend: If you want convenience and are using the stack for general recovery or maintenance rather than targeting a specific injury.
The GLOW blend adds GHK-Cu as a third peptide for collagen cross-linking. If skin quality or scar reduction is also a goal, see our GLOW blend dosage guide and glow peptide dosage.
What the Evidence Actually Shows
Honest evidence grading for each component.
BPC-157: Strong preclinical, minimal human data. Over 100 animal studies show tissue repair across tendons, muscles, gut, nerves, and bone (Sikiric et al., systematic reviews, PMID: 29582151). Only 3 human pilot studies exist: an interstitial cystitis pilot (12 women, 2024), an IV safety pilot (2 adults, 2025, PMID: 40131143), and a chronic knee pain retrospective (12 patients). No Phase 3 trials. No registered trials recruiting on ClinicalTrials.gov.
TB-500: Moderate human evidence. Thymosin beta-4 (the parent molecule TB-500 is derived from) has Phase 2 clinical trial data. A multicenter RCT for dry eye showed improved symptoms versus placebo over 56 days. Heart health trials in acute MI patients showed protective effects. Wound healing trials showed accelerated closure. Safety profiles across Phase 2 trials were comparable to placebo.
The combination: Zero studies. No published study tests BPC-157 and TB-500 together in any model. The complementary mechanism theory is based on understanding each compound individually. The synergy is plausible but unproven.
For general peptide safety information, see our peptide safety guide and peptide stacking guide.
Side Effects and Safety
Both peptides have favorable safety profiles based on available data.
| Side Effect | BPC-157 | TB-500 |
|---|---|---|
| Injection site redness | Common, mild | Common, mild |
| Headache | Occasional | 10-15% |
| Nausea | Rare | 5-10% |
| Fatigue/lethargy | Rare | 10-15% |
| Old injury flare | Reported anecdotally | Reported anecdotally |
Serious concerns (theoretical):
Both peptides promote tissue growth and repair, which raises theoretical concerns for individuals with active cancer (pro-angiogenic effects could support tumor growth). This is a theoretical risk, not confirmed in human studies, but it drives the standard contraindication against use in patients with known malignancies.
Regulatory status: Neither peptide is FDA-approved. BPC-157 is classified as FDA Category 2 (cannot be compounded by licensed pharmacies). Both are prohibited by WADA at all times. A positive test carries a 4-year ban.
For more on individual side effects, see our TB-500 side effects guide and BPC-157 liver safety. For legal context, see are peptides legal and FDA peptide crackdown.
Frequently Asked Questions
What is the Wolverine peptide stack?
The combination of BPC-157 and TB-500 peptides used together for injury recovery. BPC-157 builds blood vessels at the injury site while TB-500 mobilizes repair cells systemically. The name references Wolverine's superhuman healing ability from X-Men. Neither peptide is FDA-approved.
How long does the Wolverine stack take to work?
Most users report initial improvements in 1-2 weeks, with significant progress by 4-6 weeks. Animal studies show marker changes within days. Full tissue remodeling may take 8-12 weeks. Standard protocols run 6-8 weeks.
Is there scientific proof the Wolverine stack works?
Each peptide individually has supporting evidence. BPC-157 has 100+ animal studies and 3 small human pilots. TB-500 has Phase 2 human trials for dry eye and wounds. No study has tested the two in combination. The synergy is theoretically plausible but unproven.
Should I buy a blend or separate vials?
Separate vials for targeted injury recovery (BPC-157 near the injury, TB-500 in abdomen). Blends for convenience and general recovery. Separate vials are typically cheaper and allow independent dose adjustment. Blends require one reconstitution and one injection.
Is the Wolverine stack banned in sports?
Yes. Both BPC-157 and TB-500 are prohibited by WADA at all times, in and out of competition. BPC-157 falls under unapproved substances (S0). TB-500 falls under growth factors. A positive test typically results in a 4-year ban.
How much does the Wolverine stack cost per month?
Approximately $100-200 per month for research-grade peptides bought separately. Pre-mixed blends cost slightly more. Clinic-administered protocols run $300-600+ per month. Separate vials offer the best value with full dose control.
What is the difference between the Wolverine stack and the GLOW blend?
The Wolverine stack is BPC-157 + TB-500 (two peptides). The GLOW blend adds GHK-Cu as a third peptide for collagen cross-linking and skin rejuvenation. The Wolverine stack focuses on tissue repair. The GLOW blend adds a cosmetic/skin quality component.
Can I take BPC-157 and TB-500 at the same time?
Yes. Many users inject both during the same session. BPC-157 is typically injected subcutaneously near the injury site. TB-500 is injected in the abdomen. They target different biological pathways with no known interaction.
The Bottom Line
The Wolverine stack pairs BPC-157's local tissue repair with TB-500's systemic cell mobilization. The complementary mechanism theory is sound. The evidence gap is real. Zero combination studies exist.
Each peptide individually has supporting data. BPC-157 has extensive preclinical research. TB-500 has Phase 2 human trial data. The combination is the most popular peptide stack in the recovery community, but popularity is not proof.
For individual peptide dosing, see our BPC-157 dosage guide and TB-500 dosage guide. Use our reconstitution calculator for preparation and our cost calculator for treatment planning.
This is educational content about research compounds. Consult a healthcare provider before using any peptide.
Not Sure Which Peptide Protocol Is Right for You?
Take our 2-minute quiz for a personalized recommendation based on your goals and health profile.
Start the Quiz →